Table 1

List of drugs withdrawn for safety reasons in all EU member states between 2002 and 2011 grouped by adverse drug reaction or safety concern

Drug nameDrug class or useYear first marketedYear of withdrawalLength of time on market (years)Adverse reaction or safety concern
RofecoxibNSAID (COX-2 inhibitor)199920045Thrombotic events
ThioridazineNeuroleptic (α-adrenergic and dopaminergic receptor antagonist)1958200547Cardiac disorders
ValdecoxibNSAID (COX-2 inhibitor)200320052Cardiovascular and cutaneous disorders
RosiglitazoneAntidiabetic treatment (PPAR agonist)2000201010Cardiovascular disorders
SibutramineTreatment of obesity (serotonin-noradrenaline reuptake inhibitor)1999201011Cardiovascular disorders
OrciprenalineSympathomimetic (non-specific β-agonist)1961201049Cardiac disorders
BenfluorexAnorectic and hypolipidaemic1974200935Heart valve disease—Pulmonary hypertension
ClobutinolCough suppressant (centrally acting)1961200746QT prolongation
BuflomedilVasodilator (α1 and α2 receptor antagonist)1974201137Neurological and cardiac disorders (sometimes fatal)
VeraliprideNeuroleptic (and dopaminergic receptor antagonist)1979200728Neurological and psychiatric disorders
RimonabantTreatment of obesity (cannabinoid receptor antagonist)200620082Psychiatric disorders
CarisoprodolMuscle relaxant1959200748Intoxication—Psychomotor impairment—Addiction—misuse
Aceprometazine + Acepromazine + ClorazepateHypnotic1988201123Cumulative adverse effects—misuse—fatal side effect
DextropropoxypheneOpioid painkiller∼1960200949Fatal overdose
NefazodoneAntidepressant199420039Hepatotoxicity
Ximelagatran/melagatranAnticoagulant (thrombin inhibitor)200320063Hepatotoxicity
LumiracoxibNSAID (COX-2 inhibitor)200320074Hepatotoxicity
SitaxentanAntihypertensive (endothelin receptor antagonist)200620104Hepatotoxicity
BufexamacNSAID∼1970201040Contact allergic reactions
  • EU, European Union; NSAID, non-steroidal anti-inflammatory drug.